Peptide Initiative

Peptide profile · Hormone Support

Abarelix

GnRH Antagonist for Advanced Prostate Cancer Treatment

Strong human trialsFDA approved in 2003 as PLENAXIS for…
Approximately 13 daysHalf-life
~100%Bioavailability (intramuscular depot injection)
1416.1Molecular weight, g/mol

Molecular formula

C72H95ClN14O14

CAS number
183552-38-7
PubChem
16131215
Developed · 1999
Praecis Pharmaceuticals Research Team, Praecis Pharmaceuticals (now NeoTherapeutics)

Amino acid sequence

D-Ala-D-Phe(4-Cl)-D-Ala-Ser-Tyr-D-Asp-Leu-Lys(iPr)-Pro-D-Ala-NH2

Rapid Hormone ControlRapid testosterone suppression without initial flare effect

9.0

Advanced Cancer ManagementEffective for advanced and metastatic prostate cancer

8.6

Patient TolerabilityAvoids testosterone surge seen with GnRH agonists

8.3

Ratings out of 10.

100mg

Every documented dose level

PhaseDoseFrequency
Up to 12 months (effectiveness beyond 12 months not established)100 mgDay 1, 15, 29, then every 4 weeks
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for reducing testosterone levels in prostate cancer & slowing cancer progression in advanced disease

Best for

  • Reducing testosterone levels in prostate cancer

    Abarelix is particularly well-suited for individuals focused on reducing testosterone levels in prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Slowing cancer progression in advanced disease

    Abarelix is particularly well-suited for individuals focused on slowing cancer progression in advanced disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Managing hormone-dependent cancer symptoms

    Abarelix is particularly well-suited for individuals focused on managing hormone-dependent cancer symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for hormone support supportConsult your healthcare provider for alternatives to Abarelix based on your specific needs and medical history
Alternative hormone-supporting peptidesKisspeptin-10GonadorelinPT-141 (Bremelanotide)
Non-peptide hormone supportClomiphene citrateAnastrozoleLifestyle modifications (sleep, exercise)

Do not use if

  • Pregnancy or lactation
  • Severe hypersensitivity reactions to peptide therapeutics
  • History of anaphylaxis with similar compounds

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Abarelix use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Abarelix with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Abarelix injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

10 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Abarelix carries significant safety concerns primarily related to histamine release reactions, which led to its voluntary withdrawal from the U.S.

market in 2006. Serious allergic responses including anaphylaxis, flushing, and hypotension have been documented.

Long-term use poses substantial risks of bone density loss, cardiovascular effects from hormonal suppression, and metabolic complications including weight gain and altered lipid profiles. Liver enzyme elevations occur in 5-10% of patients.

All use requires intensive medical supervision with regular monitoring of testosterone levels, liver function, bone density, and cardiovascular markers.

Abarelix was studied through Phase 3 clinical trials and FDA approval before its market withdrawal. Evidence includes the pivotal studies showing rapid testosterone suppression without initial flare, but also documented cases of serious histamine-mediated reactions.

The evidence base is primarily from the 2003-2006 approval period, with limited post-market surveillance data due to its discontinuation. No new human trials have been conducted in recent years, making current safety data approximately 20 years old.


Common side effects · experienced by some users

Mild discomfort at treatment site

Some users experience mild discomfort, which is among the most commonly reported effects with Abarelix. This typically resolves within a few days as the body adjusts.

Management
Apply ice if needed. Rotate treatment sites. These symptoms typically improve within the first week of use.

Hot flashes and sweating

Hot flashes and sweating affect approximately 40-50% of men on GnRH antagonists like abarelix. These occur due to rapid testosterone suppression and hypothalamic dysregulation. Episodes typically last 2-5 minutes and can occur multiple times daily, especially in the first 2-3 months of treatment.

Management
Wear moisture-wicking clothing. Avoid hot beverages, alcohol, and spicy foods which trigger flashes. Use fans or air conditioning. Maintain cool sleeping conditions. Regular aerobic exercise can reduce frequency. Venlafaxine (75 mg daily) or other SSRIs are often prescribed and can reduce hot flashes by 60-70%. Most patients adjust within 6-12 weeks as the body acclimates to low testosterone.

Decreased libido and sexual dysfunction

Sexual dysfunction is nearly universal (90%+ of men) on GnRH antagonists as testosterone suppresses to near-castration levels. Decreased libido, erectile dysfunction, and reduced ejaculate volume are expected consequences of intentional testosterone suppression for prostate cancer treatment. These effects are reversible upon treatment discontinuation.

Management
Discuss sexual health openly with your oncologist—this is an expected part of hormone therapy. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) may help erectile dysfunction. Penile rehabilitation programs are sometimes recommended. Intimate communication with partners about expectations and alternatives is important. Most sexual function recovers gradually 6-12 months after treatment ends if appropriate.

Increased liver enzymes

Elevated liver enzymes (ALT, AST, GGT) occur in approximately 5-10% of abarelix-treated patients, usually mild and asymptomatic. Elevations typically appear within the first 1-3 months and often resolve spontaneously despite continued treatment. Severe hepatotoxicity is rare.

Management
Baseline liver function tests are essential before starting treatment. Monitor liver function every 3-6 months during treatment. Mild elevations (1-3x upper limit of normal) usually require no intervention. Reduce alcohol consumption and avoid hepatotoxic supplements. Report jaundice, dark urine, or right upper quadrant pain immediately. Treatment discontinuation is rare unless enzymes exceed 5x normal or clinical signs of liver injury appear.

Injection site reactions (pain, redness, swelling)

Injection site reactions occur in 10-20% of patients, typically mild and localized. Redness and swelling usually peak within 24-48 hours and resolve within 7-10 days. Pain ranges from minimal to moderate. Abscesses are rare (<1%). Multiple depot formulations in the same area can increase risk.

Management
Apply ice for 15 minutes immediately after injection and intermittently for 24 hours to reduce inflammation. Rotate injection sites systematically—vary the abdomen location for each subsequent injection. Use proper injection technique: clean skin thoroughly, allow alcohol to dry completely, use a 90-degree angle for needle insertion. Topical hydrocortisone cream or NSAIDs (ibuprofen 400 mg) can manage mild inflammation. Report any signs of infection (increasing warmth, spreading redness, pus) immediately.

Abdominal pain and gastrointestinal symptoms

GI symptoms (nausea, abdominal discomfort, changes in bowel habits) affect 15-25% of patients, usually mild-to-moderate. These may result from the injection itself, hormonal changes, or individual sensitivity. Most symptoms emerge in the first 2 weeks and improve as the body adapts.

Management
Eat small, frequent meals and avoid heavy, fatty, or greasy foods. Stay well-hydrated. Ginger supplements or ginger tea can help with nausea. Avoid eating immediately before or after injection—wait 1-2 hours. Over-the-counter antacids (calcium carbonate) or H2 blockers (famotidine) can help. Probiotic supplements may support GI health. If constipation develops, increase fiber intake and stay active. Report any severe, persistent abdominal pain or vomiting immediately.

Headache and dizziness

Headaches and dizziness occur in approximately 10-15% of patients and typically emerge in the first 1-2 weeks of treatment. Dizziness may relate to blood pressure fluctuations or rapid metabolic changes from hormone suppression. Most episodes are mild to moderate.

Management
Ensure adequate hydration—dehydration exacerbates dizziness. Rise slowly from lying or sitting positions to prevent orthostatic hypotension. Monitor blood pressure regularly, especially if dizziness is severe. Mild headaches often respond to acetaminophen or ibuprofen. Reduce caffeine intake, as this can worsen headaches. Rest in a cool, dark room during episodes. Report severe or persistent headaches, vision changes, or syncope immediately, as these warrant medical evaluation.

Weight changes

Weight gain of 2-5 kg (average 3-4 kg) occurs in 30-40% of abarelix-treated men, primarily from increased adipose tissue deposition. Testosterone suppression reduces basal metabolic rate by 10-15%, decreases muscle mass, and alters fat distribution. Weight changes typically stabilize after 3-6 months.

Management
Implement regular aerobic exercise (150+ minutes weekly) and resistance training to preserve muscle mass and maintain metabolic rate. Maintain consistent caloric intake—increased hunger is common but doesn't require eating more. Focus on high-protein diet (1.2-1.6 g/kg) to protect muscle. Monitor weight weekly. Mediterranean or DASH diets are often recommended. Discuss with a dietitian if weight gain exceeds 5 kg, as this may affect comorbidities like diabetes or hypertension.

Gynecomastia (breast tissue enlargement)

Gynecomastia (breast tissue growth) occurs in 5-15% of men on long-term GnRH antagonist therapy, typically appearing after 3-6 months of treatment. Low testosterone shifts the androgen-to-estrogen balance, and peripheral aromatization of residual androgens to estrogen becomes relatively more significant. Breast tissue tenderness often accompanies enlargement.

Management
Baseline breast imaging (ultrasound or mammography if >50 years old) is recommended to exclude malignancy. Topical NSAIDs (diclofenac) may reduce tenderness. Tamoxifen (10-20 mg daily) or anastrozole can prevent or reduce gynecomastia if started early. Gynecomastia typically regresses partially after treatment discontinuation, but may persist in some patients. Discuss surgical options with your oncologist if gynecomastia becomes cosmetically or functionally bothersome.

Bone density loss with long-term use

Androgen deprivation therapy causes significant bone loss, with hip and spine BMD declining 2-3% per year during treatment. Fracture risk increases substantially—vertebral compression fractures can occur in 10-20% of men on prolonged GnRH therapy. Older men and those with pre-existing osteopenia face highest risk. This is one of the most clinically significant toxicities of long-term GnRH antagonism.

Management
Baseline DXA (bone density) scan is essential before starting therapy and should be repeated annually. Ensure adequate calcium (1200 mg/day) and vitamin D (1000-2000 IU daily, target 25-OH vitamin D >30 ng/mL). Weight-bearing exercise (walking, resistance training) 30 minutes most days protects bone. Bisphosphonates (alendronate, zoledronic acid) should be considered, especially if T-score <-1.0. Denosumab (RANKL inhibitor) is an alternative if bisphosphonates are contraindicated. Limit alcohol and avoid smoking. Monitor for new back pain or height loss, which may indicate compression fractures.

Serious side effects

Severe allergic reaction

In rare cases, Abarelix may trigger a severe allergic reaction including difficulty breathing, facial swelling, or widespread rash. This requires immediate medical attention.

Management
STOP treatment immediately and seek emergency medical care. Do not restart without medical clearance. Report all allergic reactions to your healthcare provider.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Abarelix
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Abarelix should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeBicalutamide (antiandrogen for added testosterone blocking) — May be used together under medical guidance.
  • SafeSupportive hormone replacement therapy (as directed) — May be used together under medical guidance.
  • SafeBone-protective agents for long-term therapy — May be used together under medical guidance.

With medications

  • CautionOther GnRH agonists simultaneously — Use with caution—discuss with your healthcare provider.
  • CautionCertain antiandrogens without medical supervision — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Abarelix. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs days 1-7

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

FDA approved in 2003 as PLENAXIS for advanced symptomatic prostate cancer; discontinued and no longer marketed in the US

Onset of effects

Moderate

(1-2 weeks)


How it works

Abarelix works like a GnRH antagonist, immediately blocking testosterone production in men with prostate cancer.

Unlike older treatments that first stimulate hormone release before suppressing it, abarelix goes straight to blocking the hormones, providing rapid control without the initial surge.

The deeper mechanism

Abarelix is a synthetic decapeptide GnRH antagonist with modifications providing competitive blockade at pituitary GnRH receptors. Unlike agonists, abarelix prevents FSH/LH release without initial stimulation, rapidly suppressing testosterone to castration levels within 48 hours.


What to expect

  1. Days 1-7

    What you might notice

    • Rapid GnRH receptor blockade begins
    • Testosterone suppression starts without initial surge

    What's normal

    • Initial response to Abarelix is beginning at the cellular level
    • Different individuals experience Abarelix's onset at different rates
    • Transient systemic effects from initial Abarelix exposure are common

    What's next

    • Maintain consistent Abarelix administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  2. Weeks 2-4

    What you might notice

    • Testosterone levels reach castration levels (less than 50 ng/dL)
    • Hormonal effects (hot flashes, decreased libido) may appear

    What's normal

    • Abarelix is now achieving steady-state pharmacokinetics
    • Measurable changes aligned with Abarelix's mechanism may appear
    • Initial adjustment effects typically resolve by this point

    What's next

    • Maintain Abarelix dosing exactly as established
    • Track progress toward intended outcomes in detail
    • Review lab work or biomarker changes with your healthcare team
  3. Months 2-6

    What you might notice

    • Sustained testosterone suppression maintained with monthly injections
    • Cancer progression slowed;
    • continuous hormonal control maintained

    What's normal

    • Full therapeutic effects of Abarelix are well-characterized at this point
    • Maintenance of Abarelix's therapeutic effects is typical
    • Tolerance patterns with Abarelix are generally stable over months

    What's next

    • Comprehensive assessment of Abarelix efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Abarelix over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

4 registered studies, 1 still enrolling.

4registered studies
1recruiting now
2phase 3 or 4
0with published results

By phase

Phase 4

1

Phase 3

1

Phase 2

1

No phase

1

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

4

Records only

0

About 2,299 people took part in the studies that actually administered Abarelix. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • NCT06157528 Not Yet Recruiting100 enrolled

    Diagnosis of Pelvic Endometriosis in MRI

    Zhenshen Ma

  • NCT00103623 Phase 4Suspended2,000 enrolled

    The Plenaxis® Experience Study

    PRAECIS Pharmaceuticals Inc.

  • NCT00100243 Phase 2Completed22 enrolled

    Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

    PRAECIS Pharmaceuticals Inc.

See all 4 trials for Abarelix

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Abarelix is named as an intervention; studies that only mention it in passing are not.

Why was Abarelix withdrawn from the U.S. market?

Praecis Pharmaceuticals voluntarily withdrew Plenaxis in June 2006, primarily due to limited market adoption and the availability of alternative GnRH therapies. Some reports cited rare but serious allergic reactions (anaphylaxis) in a small number of patients.

How is Abarelix different from GnRH agonists like leuprolide?

Abarelix is a GnRH antagonist that blocks GnRH receptors immediately, preventing the initial testosterone surge (flare effect) seen with agonists. Agonists first stimulate GnRH receptors before causing feedback suppression, creating a temporary testosterone spike.

What is the advantage of no testosterone flare?

The testosterone flare from agonists can temporarily worsen prostate cancer symptoms and increase pain. Abarelix avoids this by antagonizing GnRH directly, making it safer for patients with advanced disease.

Is Abarelix still available?

In the United States, Abarelix is no longer available due to its 2006 withdrawal. However, it remains marketed in some countries including Germany and other European markets under the name Plenaxis.

What should I monitor while on Abarelix therapy?

Regular monitoring should include testosterone levels, liver function tests, bone density (DXA scans), PSA levels, and clinical symptoms. Injection sites should be inspected for reactions. Any signs of allergic reaction (rash, difficulty breathing, swelling) require immediate medical attention.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Abarelix, on one page.

Abarelix dosing protocol

Medical disclaimer

Abarelix is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

100 mg Day 1, 15, 29, then every 4 weeks · onset 1-2 weeks
Open the Abarelix calculatorAbarelix calculator